^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Loqtorzi (toripalimab-tpzi) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation

    Excerpt:
    ...Harboring EGFR mutation (19del or L858R); 5....
    Trial ID:
    NCT05962021
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    The study of Triprilimab therapy with cytokine induced killer cells in advanced non-small cell lung cancer

    Excerpt:
    ......
    Trial ID:
    ChiCTR2000035573
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer

    Excerpt:
    ...histomolecular pathology confirming the absence of classic driver oncogene mutations in EGFR, ALK, or ROS1....
    Trial ID:
    NCT05798845
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment

    Excerpt:
    ...- Histologically and/or cytologically confirmed advanced or recurrent non-small cell lung cancer with EGFR sensitive mutation (exon 19 deletion, exon 21 L858R), and meeting the following conditions at the same time:...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC

    Excerpt:
    ...- Exact evidence confirms the presence of EGFR, ALK, ROS 1 gene mutations in non-small cell lung cancer....
    Trial ID:
    NCT05055583
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    neoadjuvant PD-1 inhibitor (Toripalimab) plus chemotherapy in stage Ⅱ-Ⅲ NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.

    Excerpt:
    ...Without specific driven gene mutation like EGFR, ALK, KRAS and so on. ...
    Trial ID:
    ChiCTR1900024014
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Signal Transduct Target Ther
    Title:

    Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial

    Published date:
    10/15/2021
    Excerpt:
    Toripalimab plus chemotherapy showed a promising anti-tumor activity with acceptable safety profiles as the second-line setting in patients with EGFR-mutant NSCLC.
    Secondary therapy:
    carboplatin + pemetrexed
    DOI:
    https://doi.org/10.1038/s41392-021-00751-9
    Trial ID:
    NCT03924050